Free Trial

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Belite Bio, Inc stock logo
BLTE
Belite Bio
$66.61
+10.0%
$52.32
$31.00
$70.36
$2.04B-1.551,247 shs122,150 shs
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
$38.46
-1.8%
$40.22
$23.14
$45.23
$1.83B1.14564,672 shs246,795 shs
MannKind Co. stock logo
MNKD
MannKind
$7.07
+0.7%
$6.33
$3.17
$7.14
$1.93B1.312.60 million shs3.69 million shs
Xencor, Inc. stock logo
XNCR
Xencor
$21.01
0.0%
$19.77
$15.31
$26.84
$1.30B0.67600,435 shs341,783 shs
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Belite Bio, Inc stock logo
BLTE
Belite Bio
-13.23%-6.82%+29.16%+24.74%+61.42%
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
+0.31%+1.98%+0.46%-2.37%+42.84%
MannKind Co. stock logo
MNKD
MannKind
+2.18%+8.17%+11.61%+26.49%+63.64%
Xencor, Inc. stock logo
XNCR
Xencor
-2.55%-0.33%+4.53%+5.63%+21.15%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Belite Bio, Inc stock logo
BLTE
Belite Bio
1.1254 of 5 stars
1.53.00.00.03.40.80.6
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
4.6843 of 5 stars
4.61.00.04.22.93.30.6
MannKind Co. stock logo
MNKD
MannKind
1.6622 of 5 stars
2.60.00.00.02.01.71.9
Xencor, Inc. stock logo
XNCR
Xencor
4.0092 of 5 stars
3.53.00.03.92.70.00.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Belite Bio, Inc stock logo
BLTE
Belite Bio
3.00
Buy$59.00-11.42% Downside
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
3.17
Buy$56.8247.73% Upside
MannKind Co. stock logo
MNKD
MannKind
3.14
Buy$8.6722.58% Upside
Xencor, Inc. stock logo
XNCR
Xencor
3.00
Buy$34.7865.53% Upside

Current Analyst Ratings

Latest BLTE, MNKD, XNCR, and MIRM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/17/2024
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$47.00 ➝ $49.00
10/11/2024
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$66.00 ➝ $66.00
9/26/2024
Xencor, Inc. stock logo
XNCR
Xencor
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$31.00 ➝ $34.00
9/12/2024
Belite Bio, Inc stock logo
BLTE
Belite Bio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$60.00 ➝ $60.00
9/9/2024
MannKind Co. stock logo
MNKD
MannKind
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
9/9/2024
MannKind Co. stock logo
MNKD
MannKind
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$7.00 ➝ $8.00
9/9/2024
Xencor, Inc. stock logo
XNCR
Xencor
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$34.00
8/28/2024
MannKind Co. stock logo
MNKD
MannKind
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$10.00 ➝ $12.00
8/13/2024
Belite Bio, Inc stock logo
BLTE
Belite Bio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$59.00 ➝ $60.00
8/13/2024
Belite Bio, Inc stock logo
BLTE
Belite Bio
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$57.00 ➝ $57.00
8/8/2024
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$50.00 ➝ $60.00
(Data available from 10/31/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Belite Bio, Inc stock logo
BLTE
Belite Bio
N/AN/AN/AN/A$3.28 per shareN/A
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
$264.38M6.94N/AN/A$5.33 per share7.22
MannKind Co. stock logo
MNKD
MannKind
$248.37M7.75N/AN/A($0.91) per share-7.77
Xencor, Inc. stock logo
XNCR
Xencor
$133.62M9.70N/AN/A$10.99 per share1.91

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Belite Bio, Inc stock logo
BLTE
Belite Bio
-$31.63M-$1.23N/AN/AN/AN/A-39.84%-37.97%11/11/2024 (Estimated)
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
-$163.41M-$2.29N/AN/AN/A-40.34%-43.47%-16.35%11/7/2024 (Estimated)
MannKind Co. stock logo
MNKD
MannKind
-$11.94M$0.03176.7941.59N/A4.73%-11.97%6.64%11/5/2024 (Estimated)
Xencor, Inc. stock logo
XNCR
Xencor
-$126.09M-$2.19N/AN/AN/A-132.74%-28.23%-20.61%11/5/2024 (Estimated)

Latest BLTE, MNKD, XNCR, and MIRM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/9/2024Q2 2024
Belite Bio, Inc stock logo
BLTE
Belite Bio
-$0.28-$0.31-$0.03-$0.31N/AN/A
8/7/2024Q2 2024
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
-$0.47-$0.52-$0.05-$0.52$75.03 million$77.90 million      
8/7/2024Q2 2024
MannKind Co. stock logo
MNKD
MannKind
$0.01$0.05+$0.04$0.11$64.81 million$72.39 million    
8/5/2024Q2 2024
Xencor, Inc. stock logo
XNCR
Xencor
-$0.82-$1.07-$0.25-$1.07$21.13 million$16.96 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Belite Bio, Inc stock logo
BLTE
Belite Bio
N/AN/AN/AN/AN/A
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
N/AN/AN/AN/AN/A
MannKind Co. stock logo
MNKD
MannKind
N/AN/AN/AN/AN/A
Xencor, Inc. stock logo
XNCR
Xencor
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Belite Bio, Inc stock logo
BLTE
Belite Bio
N/AN/AN/A
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
1.34
3.28
3.09
MannKind Co. stock logo
MNKD
MannKind
N/A
4.07
3.76
Xencor, Inc. stock logo
XNCR
Xencor
0.02
6.92
6.92

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Belite Bio, Inc stock logo
BLTE
Belite Bio
0.53%
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
N/A
MannKind Co. stock logo
MNKD
MannKind
49.55%
Xencor, Inc. stock logo
XNCR
Xencor
N/A

Insider Ownership

CompanyInsider Ownership
Belite Bio, Inc stock logo
BLTE
Belite Bio
13.29%
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
22.87%
MannKind Co. stock logo
MNKD
MannKind
3.00%
Xencor, Inc. stock logo
XNCR
Xencor
5.23%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Belite Bio, Inc stock logo
BLTE
Belite Bio
2030.61 million26.54 millionNot Optionable
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
14047.71 million36.80 millionOptionable
MannKind Co. stock logo
MNKD
MannKind
400272.32 million266.75 millionOptionable
Xencor, Inc. stock logo
XNCR
Xencor
28061.66 million66.27 millionOptionable

BLTE, MNKD, XNCR, and MIRM Headlines

Recent News About These Companies

How to Take Advantage of moves in (XNCR)
(XNCR) Pivots Trading Plans and Risk Controls
Xencor Announces Upcoming Change to Board of Directors
Xencor (XNCR) Gets a Buy from RBC Capital
Slew of New Drugs Sends Xencor Shares Soaring

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Belite Bio logo

Belite Bio

NASDAQ:BLTE
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.
Mirum Pharmaceuticals logo

Mirum Pharmaceuticals

NASDAQ:MIRM
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.
MannKind logo

MannKind

NASDAQ:MNKD
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
Xencor logo

Xencor

NASDAQ:XNCR
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.